<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ocular cicatricial pemphigoid</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ocular cicatricial pemphigoid</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ocular cicatricial pemphigoid</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Foster, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John J Zone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2913441"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mucous membrane pemphigoid is a heterogeneous group of chronic inflammatory blistering diseases that affect oral, ocular, pharyngeal, laryngeal, genital, or anal mucosa. The characteristic pathologic feature that unites these disorders is the presence of linear deposits of immunoglobulin (Ig)G, IgA, IgM, or C3 in the epithelial basement membrane zone. The term ocular cicatricial pemphigoid (OCP) refers to mucous membrane pemphigoid that clinically presents as a chronic cicatrizing (scarring) conjunctivitis. Involvement of other mucosal sites and nonmucosal skin may also occur in OCP.</p><p>Left untreated, OCP eventually results in severe conjunctival scarring and visual loss secondary to keratopathy, with scarring and neovascularization. Thus, early diagnosis and prompt initiation of therapy are essential for optimal management. The treatment of OCP involves the suppression of autoimmune conjunctival inflammation via the use of systemic immunomodulatory drugs. Conscientious ocular care to minimize the secondary consequences of chronic inflammation also is important.</p><p>The pathogenesis, clinical manifestations, diagnosis, and treatment of OCP will be reviewed here. Other forms of pemphigoid are discussed separately. (See  <a class="medical medical_review" href="/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p class="headingAnchor" id="H2913448"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of OCP is estimated to be between 1 in 8000 and 1 in 46,000 ophthalmic patients [<a href="#rid1">1-4</a>]. No geographical or racial predilection has been detected.</p><p>OCP is primarily a disease of older adults, with an average age of diagnosis between the ages of 60 and 70 years [<a href="#rid5">5-7</a>]. However, due to the nonspecific conjunctival inflammation that characterizes early stage OCP, in some patients the disease may be present for years prior to recognition of the diagnosis. </p><p>OCP appears to have a predilection for women. The female to male ratio is estimated to be between 1.5:1 and 3:1 [<a href="#rid5">5</a>]. The occurrence of OCP in children is rare; as of 2011, less than 20 pediatric patients have been reported [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2913490"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The chronic, cicatrizing conjunctivitis of OCP is a manifestation of a systemic autoimmune disorder characterized by the aberrant production of antibodies that recognize normal components of the mucosal epithelial basement membrane zone. As in other forms of pemphigoid, the interaction of these antibodies with their target antigens is believed to precipitate the clinical manifestations of OCP. (See  <a class="medical medical_review" href="/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p>Several components of the basement membrane zone have been identified as potential antigenic targets in cicatricial pemphigoid, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Beta-4 peptide of alpha-6 beta-4 integrin (a transmembrane anchoring protein that links basal cell hemidesmosomes to the underlying basement membrane zone) [<a href="#rid9">9-11</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laminin 5 [<a href="#rid12">12,13</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bullous pemphigoid antigen 2 (BP 180) [<a href="#rid14">14,15</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unspecified 168 kilodalton and 45 kilodalton antigens [<a href="#rid16">16,17</a>]</p><p></p><p>In particular, in OCP, the 205 kilodalton beta-4 peptide of alpha-6 beta-4 integrin appears to be a frequent target antigen [<a href="#rid9">9,10,18</a>]. An epitope in the large cytoplasmic domain of the beta-4 peptide has the strongest binding affinity for autoantibodies in sera from patients with OCP [<a href="#rid18">18</a>]. A study has identified specific epitopes of beta-4 integrin that may be involved in the pathobiology of OCP [<a href="#rid19">19</a>].</p><p>In contrast to pemphigoid involving cutaneous surfaces, which typically manifests as disassociation of the epidermis and dermis (eg, blistering skin in bullous pemphigoid), in OCP the immune-mediated process manifests as a chronic, scarring conjunctivitis. The following sequence of events may contribute to the development of the clinical findings in OCP [<a href="#rid20">20-22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Autoantibody binding in the basement membrane zone stimulates an inflammatory cascade that involves the secretion of cytokines and the recruitment of inflammatory cells</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recruited inflammatory cells sustain inflammation through the secretion of additional proinflammatory cytokines</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The release of profibrotic cytokines by inflammatory cells, such as transforming growth factor (TGF)-beta and interferon (IFN)-gamma contributes to the development of scarring </p><p></p><p>The inciting factors for OCP are not definitively known. It is suspected that a combination of genetic susceptibility and environmental insults contributes to the production of pathogenic autoantibodies [<a href="#rid5">5</a>]. The HLA DQW7 (HLA DQ-beta*0301) allele has been identified as a potential risk factor for OCP [<a href="#rid23">23,24</a>], and medications or microbial organisms may be relevant environmental contributors. </p><p>In a small subset of patients with OCP, a potential contributing factor is detected. Cases in which topical ophthalmic medications or systemic practolol have been linked to the development of OCP (also known as pseudopemphigoid or pseudo-OCP) have been reported [<a href="#rid25">25-32</a>]. </p><p>In addition, intense conjunctival inflammation has been proposed as a potential inciting factor for OCP via a process referred to as epitope spreading [<a href="#rid33">33</a>]. The epitope spreading theory describes the immune detection of normal host antigens during tissue inflammation and the subsequent mounting of an aberrant autoimmune response against those antigens. The development of OCP following Stevens-Johnson syndrome has been attributed to this theory [<a href="#rid34">34</a>]. Additional studies are necessary to determine whether this is a legitimate pathway for the induction of OCP. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2913497"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of OCP vary according to the stage of the disease. Extraocular involvement may or may not be present.</p><p class="headingAnchor" id="H378742"><span class="h2">Ocular findings</span><span class="headingEndMark"> — </span>At the time of initial symptoms, OCP may present with unilateral eye involvement. However, bilateral disease usually develops within two to four years [<a href="#rid5">5,35</a>].</p><p>Early disease may present only with signs of a chronic or relapsing conjunctivitis, with symptoms such as tearing, irritation, burning, or mucus drainage (<a class="graphic graphic_picture graphicRef65724" href="/d/graphic/65724.html" rel="external">picture 1A</a>) [<a href="#rid36">36</a>]. Frank vesicles on the conjunctiva are infrequently detected. </p><p>As the disease progresses, fibrosis ensues, resulting in conjunctival shrinkage (<a class="graphic graphic_picture graphicRef78279" href="/d/graphic/78279.html" rel="external">picture 1B</a>). Symblephara (fibrotic adhesions between the bulbar and palpebral conjunctivae), which typically begin in the inferior fornix, can become so severe that they impair eye movement (<a class="graphic graphic_picture graphicRef54207" href="/d/graphic/54207.html" rel="external">picture 1C</a>) [<a href="#rid35">35,36</a>]. As a consequence of scarring, some patients also may develop lagophthalmos (loss of the ability to completely close the eye). </p><p>Moreover, involvement of the eyelid margin can lead to ankyloblepharon (fusion of the lid margins of the upper and lower eyelids). Inflammation and scarring in this area may also disrupt the orientation of eyelash follicles, resulting in trichiasis (inward growth of the eyelashes) or distichiasis (a duplicate row of eyelashes in which one or both grow inward against the eye) (<a class="graphic graphic_picture graphicRef75647" href="/d/graphic/75647.html" rel="external">picture 2</a>). </p><p>Visual impairment eventually occurs if OCP is not adequately controlled. Xerophthalmia leading to corneal keratinization occurs as a consequence of the destruction of the ducts of the lacrimal glands, the elimination of goblet cells, which produce the mucus component of the tear film, or the development of lagophthalmos. Additionally, direct trauma to the corneal surface in the setting of entropion or trichiasis contributes to corneal keratinization, neovascularization, and scarring (<a class="graphic graphic_picture graphicRef66981" href="/d/graphic/66981.html" rel="external">picture 3</a>) [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H378785"><span class="h2">Staging</span><span class="headingEndMark"> — </span>Staging systems have been developed to assist in the assessment of disease severity and treatment response [<a href="#rid5">5,37,38</a>]. In 1986, we proposed the following categories for the classification of OCP [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I </strong>– Chronic conjunctivitis with subepithelial fibrosis (<a class="graphic graphic_picture graphicRef65724" href="/d/graphic/65724.html" rel="external">picture 1A</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage II </strong>– Shortening of the inferior fornix (<a class="graphic graphic_picture graphicRef78279" href="/d/graphic/78279.html" rel="external">picture 1B</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage III </strong>– Symblepharon (<a class="graphic graphic_picture graphicRef54207" href="/d/graphic/54207.html" rel="external">picture 1C</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IV </strong>– End-stage disease manifesting as ankyloblepharon, severe sicca syndrome, severe ocular surface keratinization (<a class="graphic graphic_picture graphicRef66981" href="/d/graphic/66981.html" rel="external">picture 3</a>)</p><p></p><p>In the modified version of this staging system, stages II and III are further subdivided in to four groups that describe the degree of involvement (a = 0 to 25 percent, b = 25 to 50 percent, c = 50 to 75 percent, and d = 75 to 100 percent) [<a href="#rid37">37</a>]. For stage II, the designation describes the percent loss of the inferior fornix depth, while in stage III this describes the percentage of horizontal involvement by symblephara. The number of symblephara is also noted. For example, a patient with stage IIcIIIb(2) would have an eye with 50 to 75 percent loss of the inferior fornix and 25 to 50 percent involvement by two symblephara.</p><p class="headingAnchor" id="H378771"><span class="h2">Extraocular involvement</span><span class="headingEndMark"> — </span>Concomitant oral disease is common in patients with OCP. Oral lesions are estimated to occur in approximately 40 percent of patients [<a href="#rid35">35</a>]. Erosive gingivitis is the most common oral manifestation, but involvement manifesting as erosions or vesicles may also occur on the buccal mucosa, palate, alveolar ridge, tongue, and lip [<a href="#rid36">36</a>]. Other mucosal sites affected less frequently than the oral cavity include the pharynx, nose, larynx, genitalia, anus, and esophagus [<a href="#rid39">39</a>].</p><p>Compared with oral disease, a smaller subset of patients with OCP has involvement of nonmucosal skin [<a href="#rid5">5</a>]. In one study from an ophthalmologic practice, 16 percent of patients had skin disease [<a href="#rid35">35</a>]. Such patients most frequently present with inflammatory bullae and erosions on the head, neck, and upper trunk [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H2913529"><span class="h1">ESTABLISHING THE DIAGNOSIS</span><span class="headingEndMark"> — </span>The systemic immunomodulatory therapies required for the treatment of OCP are associated with a number of potential adverse effects. This, and the fact that the approach to treatment differs significantly from the therapeutic approach for some of the other disorders that clinically resemble OCP, strongly favor confirmation of the diagnosis whenever feasible (see <a class="local">'Differential diagnosis'</a> below). A conjunctival biopsy with immunohistochemical studies is a valuable tool for confirming the diagnosis in patients with clinical findings suggestive of OCP. However, clinicians must remain cognizant that inconclusive or negative results do not rule out the diagnosis.</p><p class="headingAnchor" id="H2828114"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>In patients who have extraocular lesions, such as skin or other mucosal lesions, the tissue biopsy for diagnosis should first be attempted in these more easily accessible sites [<a href="#rid33">33,35</a>]. Conjunctival biopsies are generally performed in patients with active disease limited to the ocular mucosa or in patients in whom the disease is strongly suspected despite negative or inconclusive results from extraocular biopsies.</p><p>Conjunctival biopsies should always be performed on inflamed conjunctival tissue [<a href="#rid33">33</a>]. Conjunctival biopsies may be obtained from a variety of sites; we typically biopsy the bulbar conjunctiva. The approach to cutaneous biopsies in patients with concomitant skin involvement is reviewed separately. (See  <a class="medical medical_review" href="/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Tissue biopsy'</a>.)</p><p>Negative or inconclusive results can occur due to poor biopsy technique or poor handling of the specimen. Conjunctival biopsies should only be performed by ophthalmologists, and only experienced laboratory technicians should process conjunctival tissue. Disease exacerbation and the induction of scarring are potential risks of conjunctival biopsies [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2198362"><span class="h3">Hematoxylin and eosin</span><span class="headingEndMark"> — </span>The findings in specimens stained with hematoxylin and eosin (H&amp;E) are nonspecific. Examination typically demonstrates an inflammatory infiltrate of variable intensity composed of neutrophils, macrophages, plasma cells, lymphocytes, and Langerhans cells (<a class="graphic graphic_picture graphicRef55683" href="/d/graphic/55683.html" rel="external">picture 4</a>) [<a href="#rid35">35</a>]. Squamous metaplasia may also be present (<a class="graphic graphic_picture graphicRef68490" href="/d/graphic/68490.html" rel="external">picture 5</a>). The performance of additional histopathologic stains facilitates the identification of other common features, such as decreased goblet cells (PAS stain) (<a class="graphic graphic_picture graphicRef61302" href="/d/graphic/61302.html" rel="external">picture 6</a>) and increased mast cells (Giemsa stain) [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H378882"><span class="h3">Immunohistochemistry</span><span class="headingEndMark"> — </span>Direct immunofluorescence should be performed on all conjunctival biopsy specimens. Linear deposition of immunoglobulin (Ig)G, IgA, IgM, and/or C3 is the characteristic finding (<a class="graphic graphic_picture graphicRef74474" href="/d/graphic/74474.html" rel="external">picture 7</a>). However, because the diagnostic sensitivity of direct immunofluorescence in most laboratories may be only around 50 percent, a negative test does not rule out the diagnosis [<a href="#rid40">40</a>]. </p><p>The utilization of an immunoperoxidase assay may improve the likelihood of diagnosis, and the technique should be performed if immunofluorescence is negative in a patient with clinical features strongly suggestive of OCP (<a class="graphic graphic_picture graphicRef82652" href="/d/graphic/82652.html" rel="external">picture 8</a>) [<a href="#rid35">35</a>]. In a retrospective study of 166 patients with suspected OCP, performance of an immunoperoxidase avidin-biotin-complex assay on specimens that yielded negative or inconclusive immunofluorescence results was associated with the detection of additional diagnoses of OCP [<a href="#rid40">40</a>]. The addition of the immunoperoxidase assay increased the sensitivity of testing from 52 to 83 percent.</p><p>Of note, immunohistochemical findings consistent with OCP do not definitively rule out all other possible diagnoses. Epidermolysis bullosa acquisita and linear IgA bullous dermatosis, both of which may involve skin and ocular tissue, present with similar findings [<a href="#rid33">33</a>]. Thus, other diagnostic clues are utilized to distinguish OCP from these disorders. The presence of prominent milia formation in skin lesions and the detection of antibodies against type VII collagen via enzyme-linked immunosorbent assay, immunoblotting, or immunoprecipitation support a diagnosis of epidermolysis bullosa acquisita. Predominant linear IgA binding at the basement membrane zone in combination with classic skin lesions resembling a "cluster of jewels" suggests the possibility of linear IgA bullous dermatosis. </p><p class="headingAnchor" id="H2198445"><span class="h2">Indirect immunofluorescence</span><span class="headingEndMark"> — </span>Circulating antibodies against the basement membrane zone are less consistently detected in patients with cicatricial pemphigoid than in patients with bullous pemphigoid, and are of little value for diagnosis. Reported rates of antibody detection vary widely, and the probability of a positive result may be affected by the type of technique performed and by individual patient characteristics such as the level of disease activity and sites of involvement [<a href="#rid41">41-43</a>]. </p><p class="headingAnchor" id="H2913538"><span class="h2">Other laboratory studies</span><span class="headingEndMark"> — </span>No specific laboratory assays are useful for monitoring the activity of OCP. Although one study found increased levels of tumor necrosis factor (TNF)-alpha and decreased levels of interleukin (IL)-6 in sera from patients with active OCP [<a href="#rid44">44</a>] and another study found elevated IL-6, IL-12, and IL-17 levels in conjunctival tissue of patients with OCP [<a href="#rid45">45</a>], additional studies are necessary to determine whether these assays are clinically useful [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H378908"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In addition to OCP, a wide variety of other ocular disorders can present with conjunctival inflammation or scarring. Examples include: </p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctivitis and conjunctival scarring:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Toxic epidermal necrolysis or Stevens-Johnson syndrome sequelae (see  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Epidermolysis bullosa acquisita</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Linear IgA bullous disease with cicatrizing conjunctivitis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bullous systemic lupus erythematosus (see  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Bullous cutaneous lupus erythematosus'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenoviral conjunctivitis sequelae (see  <a class="medical medical_review" href="/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Viral conjunctivitis'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Paraneoplastic pemphigus (see  <a class="medical medical_review" href="/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sebaceous cell carcinoma of the conjunctiva (see  <a class="medical medical_review" href="/d/html/97893.html" rel="external">"Sebaceous carcinoma"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intraepithelial epithelioma (squamous cell carcinoma of the conjunctiva)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Corynebacterium diphtheriae conjunctivitis </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctival scarring:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Damage from ionizing radiation </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trauma </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Porphyria cutanea tarda (see  <a class="medical medical_review" href="/d/html/7108.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progressive systemic sclerosis (scleroderma) (see  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital ichthyosiform erythroderma (see  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'Lamellar ichthyosis and congenital ichthyosiform erythroderma'</a>)</p><p></p><p>The clinical history and assessment of other signs and symptoms are often useful for narrowing the differential diagnosis. If OCP remains in the differential, a biopsy of involved skin or mucosal tissues can be of value. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p class="headingAnchor" id="H464168"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>All patients with known or suspected OCP require referral to an ophthalmologist, preferably one with significant experience in this disease. Additionally, treatment should be managed by a clinician with expertise in immunosuppressive therapy, such as an ophthalmologist, dermatologist, rheumatologist, hematologist, or other clinician who is comfortable with this role. </p><p>Continued ophthalmology follow-up is essential for evaluating the response to therapy. Moreover, the presence of extraocular involvement warrants assessment and follow-up by specific clinical specialists based upon the sites of disease (eg, dermatologist, dentist, otolaryngologist, or gastroenterologist). (See <a class="local">'Extraocular involvement'</a> above.)</p><p class="headingAnchor" id="H2913554"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The primary goal of treatment in OCP is the prevention of scarring and vision loss. Whenever possible, patients should be managed by clinicians who have experience in treating this disease.</p><p>The most important therapeutic interventions are the initiation of systemic immunomodulatory drugs to suppress conjunctival inflammation and the implementation of practices that minimize secondary ocular damage. While patients with mild to moderate conjunctival inflammation and slowly progressing disease can often be managed with ocular care and conventional immunomodulatory therapies such as <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, patients with more aggressive or refractory disease typically require treatment with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. In addition, several studies suggest that intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> may have benefits for severe cases.</p><p class="headingAnchor" id="H192358"><span class="h2">Ocular care</span><span class="headingEndMark"> — </span>A variety of nonpharmacologic measures are beneficial in the management of OCP:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular lubrication </strong>– Xerophthalmia (dry eye) can lead to corneal damage, and the liberal use of ocular lubricants may help to prevent vision loss. Punctual plugs and punctual cautery, which prevent drainage of liquid from the eye, also can be helpful in the treatment of xerophthalmia [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and treatment of infection </strong>– Patients with OCP are at increased risk for ocular infections due to the presence of a compromised ocular surface [<a href="#rid46">46</a>]. The use of lid hygiene techniques on a daily basis may minimize the occurrence of ocular infections [<a href="#rid35">35</a>]. We instruct patients to apply warm compresses for two minutes followed by vertical lid massage (10 strokes downward on the upper lid and 10 strokes upward on the lower lid) twice daily. This procedure expresses the lipid contents of the meibomian glands. Prompt identification and treatment of infections also is important. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eyelash removal </strong>–<strong> </strong>Injury to the cornea as a result of trichiasis (inward turning of the eyelashes) can lead to visual impairment or blindness if left untreated. Eyelashes can be removed temporarily with manual epilation or permanently with cryoepilation or electrolysis. Cryoepilation should be performed when the disease is well controlled to reduce the risk for procedure-related exacerbations of OCP [<a href="#rid35">35,46</a>]. Other potential adverse effects of cryoepilation include ocular edema and depigmentation.</p><p></p><p class="headingAnchor" id="H192070"><span class="h2">Mild to moderate disease</span><span class="headingEndMark"> — </span>In 2004, an international consensus panel of experts released recommendations for the medical management of patients with mucous membrane pemphigoid, which included patients with OCP. Based upon a review of the published literature and clinical experience, the consensus panel concluded that <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> (50 to 200 mg/day for 12 weeks) was an appropriate initial therapy for patients with mild ocular disease [<a href="#rid33">33</a>]. A systematic review of randomized trials and uncontrolled studies also found evidence to support the use of dapsone in cicatricial pemphigoid [<a href="#rid47">47</a>].</p><p>Although there are relatively fewer data on other systemic therapies such as <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, these agents have also been used successfully by clinicians (including ourselves) for patients with OCP. No randomized trials have been performed that compare the efficacy of these therapies in OCP. Thus, factors such as concern for drug adverse effects, patient tolerance, drug availability, and drug cost heavily influence the choice of therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dapsone</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">Dapsone</a> is a sulfonamide antibiotic with antiinflammatory properties and proven efficacy in OCP [<a href="#rid5">5,6,33,47</a>]. The benefit of dapsone for ocular involvement was documented in a 12-week randomized trial in which 40 patients with stage III (see <a class="local">'Staging'</a> above), biopsy-proven OCP were treated with either dapsone (2 mg/kg per day) or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (2 mg/kg per day) [<a href="#rid5">5</a>]. Among the 20 patients treated with dapsone, 14 (70 percent) had complete suppression of conjunctival inflammation and scar formation. All of the patients treated with cyclophosphamide responded, but we reserve the use of cyclophosphamide for patients with severe or refractory disease. (See <a class="local">'Severe or refractory disease'</a> below.) </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">Dapsone</a> was also effective in a retrospective study in which the majority of patients had stage III, biopsy-proven OCP [<a href="#rid6">6</a>]. Dapsone (2 mg/kg per day for at least three months) inhibited cicatrization in 31 of 69 patients (45 percent), including 26 of 28 patients with milder conjunctival inflammation defined as &lt;2+ severity on a 0 to 4+ scale (93 percent). </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">Dapsone</a> is typically administered in doses of 50 to 200 mg per day [<a href="#rid33">33</a>]. A 12-week period is a reasonable trial of therapy; alternative therapy should be considered if no response is observed after this time [<a href="#rid33">33</a>]. Hemolytic anemia is a common adverse effect of dapsone that occurs to some degree in most patients who take dapsone but can be catastrophic in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency [<a href="#rid48">48,49</a>]. In addition, idiosyncratic leukopenia and aplastic anemia may occur in the first three months of treatment; thus, patients must receive frequent hematologic monitoring early in the course of therapy. Methemoglobinemia, another potential adverse effect of dapsone, is a dose-dependent event unrelated to G6PD status.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> and sulfapyridine are additional sulfonamide agents that have been used in the management of patients with OCP [<a href="#rid50">50,51</a>]. These agents may be less effective than <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> is a <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> antagonist that may improve OCP [<a href="#rid52">52,53</a>]. Methotrexate (5 to 25 mg given once weekly) was effective in a retrospective study of 17 patients with non-drug-induced OCP (12 patients) or drug-induced OCP (5 patients). Fifteen patients (88 percent, including all patients with drug-induced disease) achieved or maintained complete control of inflammation and 12 out of 17 patients (71 percent, including all but one patient with drug-induced disease) had no progression of cicatrization [<a href="#rid52">52</a>]. A potential limitation of this study is that only four patients had biopsy-proven OCP. </p><p></p><p class="bulletIndent1">Gastrointestinal distress, oral ulcers, myelosuppression, hepatotoxicity, pulmonary fibrosis, and renal toxicity are potential adverse effects of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. The coadministration of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> may lessen the gastrointestinal symptoms and oral ulcers. Dose adjustments are necessary if methotrexate must be administered in patients with renal insufficiency. The drug also is teratogenic and is relatively contraindicated in patients who abuse alcohol or who have preexisting liver disease. (See  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycophenolate</strong><strong> mofetil </strong>– <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil is an immunosuppressive agent that reversibly inhibits de novo purine synthesis via inhibition of the enzyme inosine monophosphate dehydrogenase. In a retrospective study in which mycophenolate mofetil (500 to 1000 mg twice daily) was given to 34 patients who had failed <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and a sulfonamide or who received mycophenolate mofetil as a step-down therapy after <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, the drug was beneficial [<a href="#rid50">50</a>]. Out of 46 treatment episodes in which mycophenolate mofetil was the principal treatment agent, 59 percent were associated with complete clinical resolution of conjunctival inflammation. When only treatment episodes in patients with biopsy-proven disease were considered (11 episodes), the response rate rose to 73 percent.</p><p></p><p class="bulletIndent1">Additional support for the efficacy of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil stems from a separate retrospective study in which 19 of 23 OCP patients treated with mycophenolate mofetil (500 mg twice daily, then adjusted according to response) achieved control of inflammation within one year, including 16 of 19 who received mycophenolate mofetil as monotherapy [<a href="#rid54">54</a>]. In another retrospective study of 38 patients who received mycophenolate mofetil (with or without initial concomitant <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) for OCP, complete or partial responses occurred in 11 and 14 of the 34 patients available for follow-up at 12 months (32 and 41 percent, respectively) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil is generally a well-tolerated drug, with gastrointestinal distress (eg, nausea, vomiting, diarrhea) as its most common associated adverse effect. Additionally, mycophenolate mofetil may induce cytopenia and the drug has teratogenic effects. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azathioprine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a>, a purine derivative that exerts immunosuppressive effects through the inhibition of RNA and DNA synthesis and repair, has been effective for OCP in case reports and retrospective studies [<a href="#rid6">6,50,56,57</a>]. In a retrospective study in which 60 patients received azathioprine as principal therapy after failure to respond sufficiently to a sulfonamide or as a step-down therapy after <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, azathioprine controlled ocular inflammation in 47 percent of 80 treatment episodes in all patients and 48 percent of 37 treatment episodes in patients with biopsy-proven OCP [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent1">Bone marrow suppression is a potential severe adverse effect of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, which may be related to the activity of thiopurine methyltransferase (TPMT), an enzyme involved in the metabolism of the drug. The assessment of TPMT activity should be performed prior to the administration of azathioprine. Dose adjustments may be necessary based upon the result. (See  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="headingAnchor" id="H192078"><span class="h2">Severe or refractory disease</span><span class="headingEndMark"> — </span>Aggressive treatment is warranted for patients with severe or rapidly progressive OCP to minimize scarring and visual loss. Based upon the limited available data, combination therapy with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is highly effective and is the treatment of choice for severe OCP [<a href="#rid6">6,7,33</a>]. Newer evidence indicates that intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> used independently or together may also be effective. </p><p>Although systemic glucocorticoids are sometimes utilized to suppress acute inflammation in patients with OCP, they are <strong>not</strong> recommended as primary therapy due to the multiple adverse effects of long-term treatment and the high likelihood for disease relapse following tapering or discontinuation [<a href="#rid5">5</a>]. The preferred role of systemic glucocorticoids is as adjunctive therapy while awaiting the onset of action of other agents in patients with severe or rapidly progressive disease. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H192135"><span class="h3">Cyclophosphamide plus prednisone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> is an alkylating agent commonly used as an antineoplastic agent in oncology. The immunosuppressive properties of cyclophosphamide account for its beneficial effects in autoimmune blistering disease. </p><p>The efficacy of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is supported by two randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In a six-month, randomized trial, 24 patients with bilateral stage III, biopsy-proven OCP were treated with either <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (2 mg/kg per day) plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or prednisone plus a placebo pill [<a href="#rid5">5</a>]. Prednisone was administered as 1 mg/kg per day for one week followed by a taper over 12 weeks to 0.25 mg/kg every other day. Prednisone was subsequently discontinued in the cyclophosphamide group. </p><p></p><p class="bulletIndent1">By eight weeks, all 12 patients treated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> achieved complete resolution of conjunctival inflammation. In addition, progression of scarring did not occur in the cyclophosphamide group during the course of the study. In contrast, only 5 out of 12 patients in the prednisone group had complete resolution of conjunctival inflammation, and, among those who responded, disease recurred when the dose fell below 0.25 mg/kg every other day. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 12-week, randomized trial in which 40 patients with stage III, biopsy-proven OCP were treated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (2 mg/kg per day) plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> (2 mg/kg per day), all 20 patients treated with cyclophosphamide exhibited resolution of clinically evident inflammation and no patients had progression of conjunctival scarring [<a href="#rid5">5</a>]. In contrast, similar results were observed in only 14 out of 20 patients treated with dapsone. </p><p></p><p>Efficacy of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is also documented in prospective and retrospective case series [<a href="#rid58">58,59</a>].</p><p><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> can be administered orally or intravenously. A response to therapy takes approximately six to eight weeks, which provides the rationale for the use of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at the initiation of therapy [<a href="#rid5">5</a>]. We typically begin intravenous cyclophosphamide therapy with 1 g/m<sup>2</sup> given every two weeks, and adjust the dose according to the degree of resultant leukopenia. We aim to maintain the white blood cell count above 3000/mm<sup>3</sup>, the absolute neutrophil count above 1000/mm<sup>3</sup>, and the platelet count above 70,000/microL. When utilizing oral cyclophosphamide therapy we prescribe initial doses of 1 to 2 mg/kg per day [<a href="#rid33">33</a>]. Prednisone (1 to 1.5 mg/kg/day) is initiated at the same time as cyclophosphamide therapy. Once improvement is achieved, we taper the prednisone over the course of approximately three months. </p><p>As noted above, leukopenia is expected during treatment with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and a complete blood count should be monitored weekly for the first two to three months of therapy and at least monthly thereafter [<a href="#rid60">60</a>]. Gastrointestinal distress, hemorrhagic cystitis, bladder cancer, infections, hair loss, and reproductive problems such as amenorrhea, premature ovarian failure, and azoospermia also can occur with cyclophosphamide. The drug is teratogenic and, thus, is contraindicated in pregnancy. (See  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p>Due to the potential long-term effects of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, we limit the duration of treatment with cyclophosphamide to 12 months. Patients who reach this duration of therapy are transitioned to other immunomodulatory agents.</p><p class="headingAnchor" id="H192142"><span class="h3">Intravenous immune globulin</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) may be effective for the treatment of OCP that is refractory to other therapies [<a href="#rid61">61-64</a>]. In a nonrandomized study of 16 patients with OCP, the administration of IVIG with gradual withdrawal of conventional therapy was associated with a shorter time to clinical remission compared with the time required in patients who were maintained on conventional therapy (4 versus 8.5 months). In addition, total control of disease activity was achieved in all patients treated with IVIG compared with only three out of eight patients who continued conventional therapy. Sustained remissions of 24 to 48 months have been reported after completion of IVIG therapy [<a href="#rid63">63</a>].</p><p>Although the initial cost of treatment with <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> can be limiting, a retrospective study in the United States that compared the cost of IVIG and conventional immunosuppressive therapy in patients with severe mucous membrane pemphigoid found that the overall cost of disease management was lower in patients treated with IVIG [<a href="#rid65">65</a>]. </p><p>Adverse effects of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> include hypersensitivity reactions, headache, vasculitis, aseptic meningitis, renal failure, myocardial infarction, and thrombosis. (See  <a class="medical medical_review" href="/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>.)</p><p class="headingAnchor" id="H192225"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B lymphocytes. Uncontrolled studies and a case report support its efficacy in OCP [<a href="#rid66">66-70</a>]. </p><p>In a series of 25 patients with biopsy-proven, severe, refractory mucous membrane pemphigoid that included 10 patients with active stage III or IV OCP, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (375 mg/m<sup>2</sup> once weekly for four weeks for one or two cycles) was associated with resolution of conjunctival inflammation in 9 of the 10 patients after one treatment cycle and in all patients after two cycles (median time to remission 10 weeks) [<a href="#rid68">68</a>]. Long-lasting improvement after rituximab occurred in 76 percent of the patients with mucous membrane pemphigoid, with maintenance of complete or partial responses during a median follow-up period of 24 months.</p><p>Of note, two patients who were simultaneously treated with systemic immunosuppressive therapy developed severe, fatal infections. Additional potential side effects of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> include nausea, serum sickness-like reactions, and infusion reactions. A boxed warning on the drug label of rituximab has been mandated by the US Food and Drug administration due to reports of progressive multifocal leukoencephalopathy. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p>Combination therapy with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> may be of value for the management of patients with severe OCP. In a retrospective study of 12 patients with OCP that was refractory to conventional therapies, disease progression ceased in the six patients who were treated with rituximab and IVIG and in none of the patients who were given other aggressive therapies (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, and/or IVIG) [<a href="#rid67">67</a>]. Additional studies are necessary to explore the efficacy of rituximab with and without IVIG.</p><p class="headingAnchor" id="H192251"><span class="h3">Other</span><span class="headingEndMark"> — </span>Other systemic therapies that have been used for patients with severe or refractory OCP include subcutaneous cytosine arabinoside and daclizumab [<a href="#rid35">35</a>]. Oral <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and oral <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> are <strong>poorly effective</strong> for arresting disease progression in OCP [<a href="#rid71">71,72</a>]. </p><p class="headingAnchor" id="H379217"><span class="h2">Local therapy</span><span class="headingEndMark"> — </span>Local therapy with agents such as topical corticosteroids, topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and topical or subconjunctival <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> C has a limited role in the management of OCP, as they have no effect on suppressing the underlying immune dysfunction [<a href="#rid5">5,73-75</a>].</p><p class="headingAnchor" id="H379224"><span class="h2">Surgical intervention</span><span class="headingEndMark"> — </span>Surgical procedures are used to treat ocular damage related to OCP. Examples include the removal of symblephara that inhibit lid function, the repair of entropion, and the use of surgical procedures that address visual impairment due to corneal damage. Corneal procedures that have been used in OCP include amniotic membrane transplantation, limbal stem cell transplantation, lamellar or penetrating keratoplasty (corneal transplants), and the placement of keratoprostheses (artificial corneas) [<a href="#rid35">35</a>].</p><p>Prior to the performance of ocular surgery, complete control of inflammation should be obtained with immunomodulatory drugs to improve the likelihood of a good surgical outcome. In addition, the level of immunosuppression is typically increased in the perioperative period to reduce the risk of surgery-induced disease exacerbations [<a href="#rid35">35,36</a>]. </p><p class="headingAnchor" id="H2913561"><span class="h1">PROGNOSIS AND CESSATION OF THERAPY</span><span class="headingEndMark"> — </span>In most patients, OCP is a slow, progressive disease process. Advancement of the disease from initial conjunctival inflammation to end-stage disease characterized by bilateral blindness may take 10 to 30 or more years [<a href="#rid5">5</a>]. However, some patients progress more quickly, and periods of severe exacerbation and rapid scarring may occur. Early identification of the disease and the prompt implementation of appropriate treatment are key factors in the prevention of adverse disease sequelae.</p><p>Although OCP is a chronic, relapsing disease, long-term remission amounting to cure of the disease is possible in some patients [<a href="#rid7">7,50,76</a>]. In one series of 104 patients followed for an average of four years, prolonged periods of remission off therapy occurred in approximately one-third of patients (average length of remission of 34 months, range 2 to 75 months) [<a href="#rid71">71,76</a>]. Since disease relapse is unpredictable, continued long-term follow-up of patients in remission is essential. </p><p>We proceed with attempts to slowly taper therapy in patients in whom disease activity (conjunctival inflammation) has been quiescent for two years. Inflammation related to trichiasis or glandular dysfunction may be confused with active pemphigoid, and interventions to minimize the effects of such findings are important for the accurate assessment of disease status. (See <a class="local">'Ocular care'</a> above.)</p><p class="headingAnchor" id="H186297952"><span class="h1">CATARACT SURGERY</span><span class="headingEndMark"> — </span>Cataracts are a common occurrence in patients with OCP, a finding related to the age at which OCP typically occurs and the chronic use of topical or systemic corticosteroids for treatment. Data on cataract surgery in patients with OCP are limited, and there is concern that surgery may induce exacerbations of conjunctival inflammation and contribute to the progression of OCP. (See  <a class="medical medical_review" href="/d/html/6904.html" rel="external">"Cataract in adults"</a>.)</p><p>However, case series document successful cataract surgery in patients with OCP, suggesting that cataract surgery can be safely performed in patients in whom optimal medical control of OCP is achieved prior to cataract surgery [<a href="#rid77">77-79</a>]. The author has successfully performed cataract surgery with posterior lens chamber implantation (small incision surgery without suture or disturbance of the conjunctiva) in many patients with quiescent OCP through perioperative management with oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg for two days prior to surgery and for ten or more days postoperatively), continuation of the chemotherapeutic agent that put the OCP into remission until at least six months after surgery, and the use of topical corticosteroids and topical antibiotics as adjunctive therapies.</p><p class="headingAnchor" id="H596439343"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/132083.html" rel="external">"Society guideline links: Mucous membrane pemphigoid"</a>.)</p><p class="headingAnchor" id="H2913568"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Ocular cicatricial pemphigoid (OCP) is a form of mucous membrane pemphigoid that manifests as a chronic cicatrizing conjunctivitis. Early diagnosis and treatment are essential for the prevention of severe scarring and blindness. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– OCP is a relatively uncommon disorder that preferentially affects older adults. Women are more likely to be affected than men. OCP rarely occurs in children. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The pathogenesis of OCP is likely to involve the stimulation of an inflammatory response by autoantibodies that bind to normal components of the conjunctival basement membrane zone. The beta-4 peptide of alpha-6 beta-4 integrin appears to be a frequent target antigen. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– The clinical findings in OCP vary according to the stage of the disease. Disease initially manifests as a chronic conjunctivitis and progresses to conjunctival fibrosis manifesting and conjunctival contracture or symblepharon (<a class="graphic graphic_picture graphicRef65724 graphicRef78279 graphicRef54207" href="/d/graphic/65724.html" rel="external">picture 1A-C</a>). Xerophthalmia (dry eye) and trichiasis (inward turning of the eyelashes) are additional common findings (<a class="graphic graphic_picture graphicRef75647" href="/d/graphic/75647.html" rel="external">picture 2</a>). Corneal damage resulting in visual impairment may also occur (<a class="graphic graphic_picture graphicRef66981" href="/d/graphic/66981.html" rel="external">picture 3</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The treatments used for the management of OCP have multiple potential adverse effects, and confirmation of the diagnosis with immunohistochemical studies on biopsy specimens should be performed whenever feasible. The characteristic immunohistochemical finding is linear deposition of IgG, IgA, or C3 along the basement membrane zone (<a class="graphic graphic_picture graphicRef74474" href="/d/graphic/74474.html" rel="external">picture 7</a>). Negative direct immunofluorescence results are common and should <strong>not</strong> be used to rule out the diagnosis. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">In patients with extraocular skin or mucosal lesions, initial biopsies for diagnosis can be performed at those sites. Conjunctival biopsies are necessary in patients with disease limited to the ocular mucosa or in those in whom the diagnosis is highly suspected despite negative extraocular biopsy results. (See <a class="local">'Biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for referral </strong>– All patients with known or suspected OCP require referral to an ophthalmologist. Whenever possible, patients should be managed by clinicians experienced in the management of this disease. (See <a class="local">'Indications for referral'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment </strong>– Systemic immunomodulatory therapy and eye care practices aimed at reducing the risk for scarring and visual impairment are the most important components of the management for patients with OCP:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mild to moderate disease </strong>– For patients with mild to moderate OCP, we recommend treatment with <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> based upon the evidence in support of its efficacy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Other effective therapies that have been less studied include <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. Topical therapy alone should <strong>not</strong> be used for the management of OCP. (See <a class="local">'Treatment'</a> above and <a class="local">'Mild to moderate disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Severe or refractory disease </strong>– Patients with severe, rapidly progressive, or refractory disease require aggressive treatment. We recommend treatment with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> are additional treatments that have shown promising results in early studies. Additional studies are necessary to determine whether these interventions should be considered first-line treatment options for severe OCP. (See <a class="local">'Severe or refractory disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bettelheim H, Kraft D, Zehetbauer G. [On the so-called ocular pemphigus (pemphigus ocularis, pemphigus conjunctivae)]. Klin Monbl Augenheilkd 1972; 160:65.</a></li><li><a class="nounderline abstract_t">Hardy WF, Lamb HD. Essential shrinkage of the conjunctiva with report of two cases. Am J Ophthalmol 1917; 34:289.</a></li><li><a class="nounderline abstract_t">Smith RC, Myers EA, Lamb HD. Ocular and oral pemphigus: Report of case with anatomic findings in eyeball. Arch Ophthalmol 1934; 11:635.</a></li><li><a class="nounderline abstract_t">BEDELL AJ. OCULAR PEMPHIGUS: A CLINICAL PRESENTATION OF KODACHROMES. Trans Am Ophthalmol Soc 1964; 62:109.</a></li><li><a class="nounderline abstract_t">Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527.</a></li><li><a class="nounderline abstract_t">Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991; 10:185.</a></li><li><a class="nounderline abstract_t">Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 2008; 115:2146.</a></li><li><a class="nounderline abstract_t">Kharfi M, Khaled A, Anane R, et al. Early onset childhood cicatricial pemphigoid: a case report and review of the literature. Pediatr Dermatol 2010; 27:119.</a></li><li><a class="nounderline abstract_t">Chan RY, Bhol K, Tesavibul N, et al. The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1999; 40:2283.</a></li><li><a class="nounderline abstract_t">Tyagi S, Bhol K, Natarajan K, et al. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci U S A 1996; 93:14714.</a></li><li><a class="nounderline abstract_t">Kumari S, Bhol KC, Simmons RK, et al. Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin. Invest Ophthalmol Vis Sci 2001; 42:379.</a></li><li><a class="nounderline abstract_t">Fujimoto W, Toi Y, Okazaki F, et al. Anti-epiligrin cicatricial pemphigoid with IgG autoantibodies to the beta and gamma subunits of laminin 5. J Am Acad Dermatol 1999; 40:637.</a></li><li><a class="nounderline abstract_t">Kirtschig G, Marinkovich MP, Burgeson RE, Yancey KB. Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. J Invest Dermatol 1995; 105:543.</a></li><li><a class="nounderline abstract_t">Bédane C, McMillan JR, Balding SD, et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997; 108:901.</a></li><li><a class="nounderline abstract_t">Balding SD, Prost C, Diaz LA, et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 1996; 106:141.</a></li><li><a class="nounderline abstract_t">Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL. Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid. J Invest Dermatol 1996; 107:136.</a></li><li><a class="nounderline abstract_t">Smith EP, Taylor TB, Meyer LJ, Zone JJ. Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid. J Invest Dermatol 1993; 101:619.</a></li><li><a class="nounderline abstract_t">Bhol KC, Dans MJ, Simmons RK, et al. The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4. J Immunol 2000; 165:2824.</a></li><li><a class="nounderline abstract_t">Rashid KA, Foster CS, Ahmed AR. Identification of epitopes within integrin β4 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report. Invest Ophthalmol Vis Sci 2013; 54:7707.</a></li><li><a class="nounderline abstract_t">Razzaque MS, Foster CS, Ahmed AR. Role of connective tissue growth factor in the pathogenesis of conjunctival scarring in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 2003; 44:1998.</a></li><li><a class="nounderline abstract_t">Elder MJ, Dart JK, Lightman S. Conjunctival fibrosis in ocular cicatricial pemphigoid--the role of cytokines. Exp Eye Res 1997; 65:165.</a></li><li><a class="nounderline abstract_t">Lambiase A, Micera A, Mantelli F, et al. T-helper 17 lymphocytes in ocular cicatricial pemphigoid. Mol Vis 2009; 15:1449.</a></li><li><a class="nounderline abstract_t">Haider N, Neuman R, Foster CS, Ahmed AR. Report on the sequence of DQB1*0301 gene in ocular cicatricial pemphigoid patients. Curr Eye Res 1992; 11:1233.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Foster S, Zaltas M, et al. Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid. Proc Natl Acad Sci U S A 1991; 88:11579.</a></li><li><a class="nounderline abstract_t">Patten JT, Cavanagh HD, Allansmith MR. Induced ocular pseudopemphigoid. Am J Ophthalmol 1976; 82:272.</a></li><li><a class="nounderline abstract_t">Hirst LW, Werblin T, Novak M. Drug induced cicatrizing conjunctivitis simulating ocular pemphigoid. Cornea 1982; 1:121.</a></li><li><a class="nounderline abstract_t">Rahi AH, Chapman CM, Garner A, Wright P. Pathology of practolol-induced ocular toxicity. Br J Ophthalmol 1976; 60:312.</a></li><li><a class="nounderline abstract_t">Gibran SK. Unilateral drug-induced ocular pseudopemphigoid. Eye (Lond) 2004; 18:1270.</a></li><li><a class="nounderline abstract_t">Fiore PM, Jacobs IH, Goldberg DB. Drug-induced pemphigoid. A spectrum of diseases. Arch Ophthalmol 1987; 105:1660.</a></li><li><a class="nounderline abstract_t">Pouliquen Y, Patey A, Foster CS, et al. Drug-induced cicatricial pemphigoid affecting the conjunctiva. Light and electron microscopic features. Ophthalmology 1986; 93:775.</a></li><li><a class="nounderline abstract_t">Butt Z, Kaufman D, McNab A, McKelvie P. Drug-induced ocular cicatricial pemphigoid: a series of clinico-pathological reports. Eye (Lond) 1998; 12 ( Pt 2):285.</a></li><li><a class="nounderline abstract_t">Bhol K, Mohimen A, Neumann R, et al. Differences in the anti-basement membrane zone antibodies in ocular and pseudo-ocular cicatricial pemphigoid. Curr Eye Res 1996; 15:521.</a></li><li><a class="nounderline abstract_t">Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.</a></li><li><a class="nounderline abstract_t">Chan LS, Soong HK, Foster CS, et al. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA 1991; 266:1543.</a></li><li><a class="nounderline abstract_t">Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res 2004; 23:579.</a></li><li><a class="nounderline abstract_t">Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43:571.</a></li><li><a class="nounderline abstract_t">Tauber J, Jabbur N, Foster CS. Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea 1992; 11:446.</a></li><li><a class="nounderline abstract_t">Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology 1981; 88:95.</a></li><li><a class="nounderline abstract_t">Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6:215.</a></li><li><a class="nounderline abstract_t">Power WJ, Neves RA, Rodriguez A, et al. Increasing the diagnostic yield of conjunctival biopsy in patients with suspected ocular cicatricial pemphigoid. Ophthalmology 1995; 102:1158.</a></li><li><a class="nounderline abstract_t">Franklin RM, Fitzmorris CT. Antibodies against conjunctival basement membrane zone. Occurrence in cicatricial pemphigoid. Arch Ophthalmol 1983; 101:1611.</a></li><li><a class="nounderline abstract_t">Chan LS, Yancey KB, Hammerberg C, et al. Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies. Arch Dermatol 1993; 129:448.</a></li><li><a class="nounderline abstract_t">Hoang-Xuan T, Robin H, Demers PE, et al. Pure ocular cicatricial pemphigoid. A distinct immunopathologic subset of cicatricial pemphigoid. Ophthalmology 1999; 106:355.</a></li><li><a class="nounderline abstract_t">Lee SJ, Li Z, Sherman B, Foster CS. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1993; 34:3522.</a></li><li><a class="nounderline abstract_t">Suelves AM, Zhao TZ, Siddique SS, Foster CS. Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients. Invest Ophthalmol Vis Sci 2012; 53:8112.</a></li><li><a class="nounderline abstract_t">Chang JH, McCluskey PJ. Ocular cicatricial pemphigoid: manifestations and management. Curr Allergy Asthma Rep 2005; 5:333.</a></li><li><a class="nounderline abstract_t">Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003; :CD004056.</a></li><li><a class="nounderline abstract_t">Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 2002; 109:111.</a></li><li><a class="nounderline abstract_t">Wertheim MS, Males JJ, Cook SD, Tole DM. Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid. Br J Ophthalmol 2006; 90:516.</a></li><li><a class="nounderline abstract_t">Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008; 115:253.</a></li><li><a class="nounderline abstract_t">Elder MJ, Leonard J, Dart JK. Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80:549.</a></li><li><a class="nounderline abstract_t">McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004; 111:796.</a></li><li><a class="nounderline abstract_t">Hervás Ontiveros A, Salom D, España Gregori E, et al. Methotrexate as a treatment in ocular cicatricial moderate pemphigoid. Arch Soc Esp Oftalmol 2014; 89:447.</a></li><li><a class="nounderline abstract_t">Nottage JM, Hammersmith KM, Murchison AP, et al. Treatment of mucous membrane pemphigoid with mycophenolate mofetil. Cornea 2013; 32:810.</a></li><li><a class="nounderline abstract_t">Hrin ML, Jorizzo JL, Feldman SR, et al. Dermatologic management of ocular mucous membrane (cicatricial) pemphigoid with mycophenolate mofetil in 38 patients. J Am Acad Dermatol 2022; 87:653.</a></li><li><a class="nounderline abstract_t">Lugović L, Buljan M, Situm M, et al. Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report. Acta Dermatovenerol Croat 2007; 15:236.</a></li><li><a class="nounderline abstract_t">Dave VK, Vickers CF. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol 1974; 90:183.</a></li><li><a class="nounderline abstract_t">Friedman J, Marcovich AL, Kleinmann G, Schattner A. Low-dose pulsed intravenous cyclophosphamide for severe ocular cicatricial pemphigoid in elderly patients. Cornea 2014; 33:1066.</a></li><li><a class="nounderline abstract_t">Munyangango EM, Le Roux-Villet C, Doan S, et al. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid. Br J Dermatol 2013; 168:381.</a></li><li class="breakAll">Perlis C, Pan TD, McDonald CJ. Cytotoxic agents. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, 2007. p.197.</li><li><a class="nounderline abstract_t">Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004; 111:303.</a></li><li><a class="nounderline abstract_t">Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999; 106:2136.</a></li><li><a class="nounderline abstract_t">Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004; 111:1380.</a></li><li><a class="nounderline abstract_t">Letko E, Bhol K, Foster SC, Ahmed RA. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study. Curr Eye Res 2000; 21:646.</a></li><li><a class="nounderline abstract_t">Daoud Y, Amin KG, Mohan K, Ahmed AR. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study. Ann Pharmacother 2005; 39:2003.</a></li><li><a class="nounderline abstract_t">Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009; 93:421.</a></li><li><a class="nounderline abstract_t">Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117:861.</a></li><li><a class="nounderline abstract_t">Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011; 147:843.</a></li><li><a class="nounderline abstract_t">Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol 2013; 68:499.</a></li><li><a class="nounderline abstract_t">Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol 2013; 69:310.</a></li><li><a class="nounderline abstract_t">Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol 1992; 82:223.</a></li><li><a class="nounderline abstract_t">Letko E, Ahmed AR, Foster CS. Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506). Graefes Arch Clin Exp Ophthalmol 2001; 239:441.</a></li><li><a class="nounderline abstract_t">Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol 2005; 6:93.</a></li><li><a class="nounderline abstract_t">Hall VC, Liesegang TJ, Kostick DA, Lookingbill DP. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 2003; 139:1083.</a></li><li><a class="nounderline abstract_t">Alonso A, Bignone ML, Brunzini M, Brunzini R. Ocular autoimmune pemphigoid and cyclosporin A. Allergol Immunopathol (Madr) 2006; 34:113.</a></li><li><a class="nounderline abstract_t">Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991; 98:858.</a></li><li><a class="nounderline abstract_t">Geerling G, Dart JK. Management and outcome of cataract surgery in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol 2000; 238:112.</a></li><li><a class="nounderline abstract_t">Puranik CJ, Murthy SI, Taneja M, Sangwan VS. Outcomes of cataract surgery in ocular cicatricial pemphigoid. Ocul Immunol Inflamm 2013; 21:449.</a></li><li><a class="nounderline abstract_t">Sainz de la Maza M, Tauber J, Foster CS. Cataract surgery in ocular cicatricial pemphigoid. Ophthalmology 1988; 95:481.</a></li></ol></div><div id="topicVersionRevision">Topic 15590 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4552348" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : [On the so-called ocular pemphigus (pemphigus ocularis, pemphigus conjunctivae)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Essential shrinkage of the conjunctiva with report of two cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ocular and oral pemphigus: Report of case with anatomic findings in eyeball</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14269885" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : OCULAR PEMPHIGUS: A CLINICAL PRESENTATION OF KODACHROMES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3296406" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2055022" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Systemic chemotherapy for ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18930554" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537062" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Early onset childhood cicatricial pemphigoid: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10476794" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8962120" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157870" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10188690" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Anti-epiligrin cicatricial pemphigoid with IgG autoantibodies to the beta and gamma subunits of laminin 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7561156" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9182819" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592065" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752852" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8409534" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10946315" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24130186" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Identification of epitopes within integrinβ4 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12714635" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Role of connective tissue growth factor in the pathogenesis of conjunctival scarring in ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9268585" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Conjunctival fibrosis in ocular cicatricial pemphigoid--the role of cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19641634" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : T-helper 17 lymphocytes in ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1490342" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Report on the sequence of DQB1*0301 gene in ocular cicatricial pemphigoid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1763074" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/782253" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Induced ocular pseudopemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Drug induced cicatrizing conjunctivitis simulating ocular pemphigoid</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/952801" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pathology of practolol-induced ocular toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044940" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Unilateral drug-induced ocular pseudopemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3318771" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Drug-induced pemphigoid. A spectrum of diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3526226" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Drug-induced cicatricial pemphigoid affecting the conjunctiva. Light and electron microscopic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9683956" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Drug-induced ocular cicatricial pemphigoid: a series of clinico-pathological reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8670753" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Differences in the anti-basement membrane zone antibodies in ocular and pseudo-ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902988" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1880886" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388075" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11004612" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1424674" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Improved detection of disease progression in ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7015218" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7037880" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9097741" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Increasing the diagnostic yield of conjunctival biopsy in patients with suspected ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6354159" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antibodies against conjunctival basement membrane zone. Occurrence in cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7682049" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9951490" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pure ocular cicatricial pemphigoid. A distinct immunopathologic subset of cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8258509" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23081979" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967079" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ocular cicatricial pemphigoid: manifestations and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535507" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11772589" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16547343" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655931" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759268" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051215" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Methotrexate therapy for ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359845" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Methotrexate as a treatment in ocular cicatricial moderate pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23132447" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of mucous membrane pemphigoid with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34929217" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dermatologic management of ocular mucous membrane (cicatricial) pemphigoid with mycophenolate mofetil in 38 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093453" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4819136" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Azathioprine in the treatment of muco-cutaneous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25014147" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Low-dose pulsed intravenous cyclophosphamide for severe ocular cicatricial pemphigoid in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22963186" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22963186" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15183151" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571350" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234140" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148601" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16264064" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321473" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20045562" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422323" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Rituximab for patients with refractory mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23200198" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23866864" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of mucous membrane pemphigoid with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1303858" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561793" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15799681" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925404" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750121" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Ocular autoimmune pemphigoid and cyclosporin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1866137" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10766278" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Management and outcome of cataract surgery in ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23941520" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Outcomes of cataract surgery in ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3050692" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cataract surgery in ocular cicatricial pemphigoid.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
